Abstract
purpose. To investigate the coding exons in the trabecular meshwork–induced
glucocorticoid response protein (TIGR) gene for
mutations in primary open-angle glaucoma (POAG) in Chinese subjects.
methods. Ninety-one Chinese patients with POAG and 113 of their family members
without glaucoma were screened for sequence alterations in the TIGR gene by polymerase chain reaction,
conformation-sensitive gel electrophoresis, and DNA sequencing. One
hundred thirty-two unrelated individuals without glaucoma, aged 50
years or more, were studied as control subjects.
results. Five sequence variants that lead to amino acid changes were identified.
One was novel: Arg91Stop in one patient with POAG. Four had been
reported: Arg46Stop in subjects with and without POAG, including an
unaffected 77-year-old woman homozygous for Arg46Stop; Gly12Arg in
subjects without glaucoma; and Asp208Glu and Thr353Ile in subjects with
and without POAG. The previously reported 1-83(G→A) and Arg76Lys
polymorphisms were detected in both patients and controls and always
occurred together.
conclusions. A different pattern of TIGR sequence variants exists in
the Chinese than in non-Chinese populations. No common TIGR mutation that causes POAG was found. The occurrence
of subjects without glaucoma who are heterozygous or homozygous for
Arg46Stop suggests that reduction in the amount of TIGR protein does
not cause glaucoma. Thus, the TIGR missense mutations
known to cause POAG probably do not cause glaucoma by inactivating a
normal TIGR function, but rather through the gain of a pathologic
function.
Glaucoma is a complex and progressive disorder of the optic
nerves and a leading cause of visual field defects and blindness in
developed countries.
1 Primary open-angle glaucoma (POAG),
which affects almost 2% of the world’s population, accounts for most
glaucoma.
2 Onset of the disease can occur at young age or
later in life, but the prevalence increases with age. The
pathophysiology of POAG is not precisely known although its cause is
clearly multifactorial. It is a result of multiple and interactive
genetic and environmental effects. Risk factors include positive family
history, age, hypertension, diabetes, smoking, and alcohol
consumption.
3 4 5
At least six associated chromosomal loci have been located for POAG:
GLC1A, GLC1B, GLC1C, GLC1D, GLC1E, and
GLC1F on
chromosomes 1q24-25, 2cen-q13, 3q21-24, 8q23, 10p, and 7q35-36
respectively.
6 7 GLC1A codes for the myocilin polypeptide,
also known as the trabecular meshwork–inducible glucocorticoid
response protein (TIGR).
8 TIGR is expressed in many eye
tissues including sclera, ciliary body, trabecular meshwork (TM), and
retina, as well as in nonocular tissues such as heart, lung, and
pancreas.
9 10 11 In the TM cells, although the mechanism is
unknown, it is suggested that mutated TIGR proteins expressed from
TIGR variants may disturb the normal cytoskeletal function
or block the movement of aqueous humor through the extracellular
spaces. Glucocorticoid causes overexpression and secretion of TIGR by
cultured TM cells, and topical glucocorticoid treatment induces
intraocular pressure (IOP) elevation in some patients with
POAG.
12 Thus, production of mutated TIGR protein with
altered structures or inappropriately high levels of TIGR protein may
contribute to glaucoma pathogenesis, causing IOP elevation. In fact,
certain
TIGR mutations have been shown to be associated with
clinical IOP elevations in patients with glaucoma who are carriers of
the mutations.
13
The
TIGR gene spans 20 kb and includes three exons. Its
promoter region is characterized by multiple-consensus steroid
hormone–responsive elements, besides other important regulatory
motifs.
10 There have been more than 30 sequence variants
reported for the
TIGR gene
within its structural domains. Among them, at least 16
(Table 1) were
shown to have strong associations with POAG.
8 10 13 14 15 16 17 18 19 20 21 22 23 24 25 The sequence changes were mainly found to be associated with exon 3 and
included missense and nonsense mutations. Some sequence variants in
exon 1 have been called probable glaucoma-causing
mutations,
13 18 26 but the number of subjects studied was
not large enough to confirm an association with POAG. However, most
sporadic occurrences of POAG do not occur in patients with mutations in
TIGR.
13 18 21 The prevalence of POAG is
affected by ethnicity. American blacks have a significantly higher
frequency than American whites.
2 Ethnic difference in the
frequency of
TIGR mutations among patients with POAG has not
been well examined, but one large study reported a range from 2.6% to
4.3% among Japanese, African-Americans, and whites.
18 So
far there has been no report on
TIGR mutations in Chinese.
In this study, we screened for
TIGR sequence alterations in
Chinese subjects with and without POAG.
Patients with POAG were recruited from the Eye Clinic of the
Prince of Wales Hospital, Hong Kong. Diagnosis of POAG required all the
following: exclusion of secondary causes (e.g., trauma, uveitis, or
steroid-induced or neovascular glaucoma); open anterior chamber angle;
IOP higher than 21 mm Hg; characteristic optic disc changes (e.g.,
vertical cup-to-disc ratio higher than 0.3); thin or notched
neuroretinal rim or disc hemorrhage; and characteristic visual field
changes with reference to Anderson’s criteria for minimal abnormality
in glaucoma.
27
Persons with POAG ranged in age from 8 to 77 years, with a mean and
median of 44.5 and 40.5 years, respectively. Some patients’ relatives
who did not have glaucoma were also included in the study. Unrelated
control subjects were recruited from patients who attended the clinic
for conditions other than glaucoma, including cataract, floaters,
refractive errors, and itchy eyes. All control subjects were at least
50 years of age. All study subjects were given a complete ocular
examination, and venous blood was collected and stored at −20°C for
less than 2 months before DNA extraction. The study protocol was
approved by the Ethics Committee for Human Research, the Chinese
University of Hong Kong, and followed the tenets of the Declaration of
Helsinki. Informed consent was obtained from the study subjects after
explanation of the nature and possible consequences of the study.
One novel amino acid sequence change was discovered in this study:
Arg91Stop. However, it was found in only one individual, a patients
with POAG. Thus, no conclusion about its effect on disease risk
could be made. Four previously published missense changes were
found: Gly12Arg, Arg76Lys, Asp208Glu, and Thr353Ile.
18 13 30 Thr353Ile was described as a probable glaucoma-causing
mutation,
18 but it was found in three control subjects in
our study
(Table 4) . Perhaps the definition of a probable
disease-causing mutation should be confined to only the sequence
alterations for which a statistically significant increase in frequency
is found among patients compared with control subjects. Functional
effects of such a mutation should also be confirmed by family linkage
analysis and, if possible, in vitro expression studies.
Gly12Arg was found only in subjects without glaucoma. When unrelated
control subjects were compared with patients with POAG
(Table 3) , there
was a trend toward an association of this sequence alteration with the
absence of POAG (Fisher’s exact two-tailed test,
P =
0.14). Any potential protective effect of Gly12Arg on glaucoma may be
confirmed by larger studies among Asian populations in which this
sequence alteration occurs.
Arg76Lys was the most common protein sequence polymorphism and
displayed no association with POAG. It always occurred with the
promoter polymorphism 1-83 (G→A), unlike other ethnic
groups.
18 That we observed no recombination between these
two sequence variants in the cases we screened raises questions about
whether any recombination events have occurred in this 309-bp interval
since this haplotype entered the Chinese population.
Asp208Glu has been reported only once before, in a Japanese patient
with ocular hypertension.
30 Although it was also found in
two patients with POAG in this study, we cannot conclude whether
Asp208Glu contributes to POAG, because it was also found in a
50-year-old normal subject.
However, many sequence alterations in
TIGR have been
identified that are likely to cause POAG.
8 10 13 14 15 16 17 18 19 20 21 22 23 24 25 Table 1 lists the mutations that have been reported in sufficiently large
case–control or family studies to give a high likelihood that they are
associated with POAG. All are in exon 3, and all but one, Gln368Stop,
are missense mutations. There are at least two ways in which
TIGR missense mutations may increase IOP: On the one hand,
they may act by inactivating a putative normal function of TIGR that
keeps IOP from increasing to excessive levels. For example, blockage of
TIGR expression has been shown to reduce flow through a cultured TM
cell layer.
31 On the other hand, the mutations may act by
inducing a pathologic activity of the TIGR protein that increases IOP.
For example, several of the mutated TIGR species appeared in the
insoluble fraction of cultured cells, unlike the normal soluble
TIGR.
32 A nonsense sequence alteration, Arg46Stop,
provides clues to choose the more likely of the above mechanisms.
The Arg46Stop protein truncation is thought to eliminate more than 90%
of the normal length of the TIGR protein, with only 13 amino acids
remaining after cleavage of the signal sequence.
12 Thus,
assuming no effects of the sequence change on expression of the normal
allele, Arg46Stop essentially reduces TIGR expression by half in
heterozygotes, and eliminates expression in homozygotes. Recently, a
Korean individual with severe juvenile-onset POAG was found to
be homozygous for Arg46Stop.
26 However, our
Arg46Stop-carrying elderly homozygote, who was 77 years of age, and all
but one of our heterozygotes did not have glaucoma, and neither did the
heterozygous relatives of the Korean homozygote (although two of them
had IOP ≥22 mm Hg). Thus, the coexistence of glaucoma with the
Arg46Stop sequence in the Korean homozygote may be due to the presence
of other genetic or environmental factors interacting with this
TIGR alteration. It may be just a coincidence due to two
probable factors: Arg46Stop may be common in Asians (3% of our control
subjects), and the proportion of patients with glaucoma in those
screened for
TIGR mutations has been much greater than in
the general population. It is tempting to interpret absence of glaucoma
in our elderly Arg46Stop homozygote as indicating that loss of TIGR
gene product does not cause glaucoma. However, because nonpenetrance
has been observed for other clearly pathogenic
TIGR mutations, we cannot currently make predictions about whether
additional Arg46Stop homozygotes are likely to develop glaucoma.
However, these findings suggest that loss of TIGR gene product alone is
not enough to result in glaucoma. Thus, these findings raise questions
about whether TIGR is essential for normal eye function or whether
other proteins can serve the function of TIGR.
Among the 11 Arg46Stop carriers in this study, including the one
homozygote identified, only one had high IOP (besides subject C155
after cataract surgery). That Arg46Stop carriers generally do not have
high IOP reduces the likelihood that the pressure increase in the
presence of missense mutations is the result of the loss of normal TIGR
function. Thus, those missense mutations are likely to be creating or
enhancing an IOP-increasing function of TIGR. The mechanism by which
these mutations lead to increased IOP is not known, but at least two
hypotheses appear reasonable: 1) TIGR protein can be secreted by TM
cells. It may then contribute to an extracellular matrix that
constricts outflow of aqueous humor through the TM. 2) TIGR protein
within TM cells may control the structure of the cytoskeleton,
affecting the shape of the cells and thus the size of the pores between
cells through which aqueous humor may exit. Some mutations may affect
binding of TIGR protein to cytoskeleton.
Glucocorticoid treatment increases expression of TIGR by TM cells, and
the time course and dose response of this expression are similar to the
effect of glucocorticoids on increasing IOP.
12 26 If an
extracellular mechanism were correct, increased expression of TIGR
protein would be expected to increase the probability of TM blockage
and increased IOP. The glucocorticoid-induced increases in both TIGR
expression and IOP are consistent with this conclusion, although
glucocorticoids may increase IOP primarily through other mechanisms.
These observations are also consistent with an intracellular mechanism
if increased TIGR protein causes TM cells to change their shape to
constrict the pores in the TM. Further study on the effects of
intracellular and extracellular TIGR protein will help elucidate the
normal and pathologic roles of TIGR.
DSCL and CPP contributed equally to the study.
Supported by the Industrial Support Fund, Hong Kong.
Submitted for publication July 14, 1999; revised September 28 and December 7, 1999; accepted December 9, 1999.
Commercial relationships policy: N.
Corresponding author: Chi Pui Pang, Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong University Eye Center, Hong Kong Eye Hospital, 3/F, 147K Argyle Street, Kowloon, Hong Kong.
[email protected] Table 1. Published Glaucoma-Associated TIGR Mutations
Table 1. Published Glaucoma-Associated TIGR Mutations
Mutation | Effect | Mean Age at Diagnosis (y) | Ethnic Group | Studies |
Gly246Arg | Change in charge; gain of turn; near Cys245 | 20, >35 | French | 10 14 15 |
Glu323Lys | Change in charge | 19 | Panamanian | 14 |
Gln337Arg | Change in charge; gain of turn | 14, >35 | Scottish | 14 16 |
Gly364Val | Change in polarity | 33 | Mixed | 8 13 14 18 |
Gln368Stop | Premature termination | 45, 62–64 | Mixed | 8 13 18 19 |
Pro370Leu | Loss of turn; near CK2 site (377-380) | 10–13 | Mixed | 10 14 15 17 21 23 |
Thr377Met | Change in polarity; loss of CK2 site (377) | 37 | Mixed | 13 14 19 |
Asp380Ala | Change in charge; loss of CK2 site? (377-380) | 30 | Mixed | 14 17 |
Lys423Glu | Change in charge; loss of cAPK consensus (422-425); no glaucoma in homozygotes | 30 | French- Canadian | 10 14 26 27 |
Val426Phe | Near cAPK site (422-425) | 26 | Mixed | 14 28 |
Tyr437His | Change in charge | 22 | Mixed | 8 13 18 |
Ile477Asn | Change in polarity; gain of turn; in CK2 site (475-478) | 18 | Mixed | 13 14 18 29 |
Ile477Ser | Change in polarity; gain of turn; in CK2 site (475-478) | 33 | French | 10 14 15 |
Asn480Lys | Change in charge; gain of α-helix; near CK2 site (475-478) | 30–35 | French | 10 14 15 |
Ile499Phe | Change in secondary structure | 31 | French | 10 14 15 |
Ser502Pro | Change in polarity | 19 | British | 17 |
Table 2. Oligonucleotide Primer Pairs for PCR
Table 2. Oligonucleotide Primer Pairs for PCR
TIGR1aF: AATCTTGCTGGCAGCGTG |
TIGR1aR: AGCTGGATTCATTGGGAC |
TIGR1bF: CTTCTGTGCACGTTGCTGCA |
TIGR1bR: CTGGTCCAAGGTCAATTGGT |
TIGR1cF: CAGTCATCCATAACTTAC |
TIGR1cR: ATATCACCTGCTGAACTC |
TIGR2F: CATAGTCAATCCTTGGGC |
TIGR2R: CTGCAGACCTGCTCTGACAA |
TIGR3aF: GGATTAAGTGGTGCTTCG |
TIGR3aR: TACGGGAACTGTCCGTGG |
TIGR3bF: GAGAAGGAAATCCCTGGAGC |
TIGR3bR: CATAAGTGACCATGTTCAAG |
TIGR3cF: ATTGACTACAACCCCCTG |
TIGR3cR: GCTTGTGGTAACCATGTAAC |
Table 3. TIGR Sequence Alterations and Restriction Endonuclease
Assays
Table 3. TIGR Sequence Alterations and Restriction Endonuclease
Assays
Amplicon | Codon Change | Nucleotide Change | Enzyme* |
1a | — | 1-83 (G → A) | AvaI (e) |
1a | Gly12Arg | 34 (G → C) | Sau96 I (e) |
1b | Arg46Stop | 136 (C → T) | EaeI (e) |
1b | Arg76Lys | 227 (G → A) | BsmAI (e) |
1b | Arg91Stop | 271 (C → T) | HindIII (c) |
2 | Asp208Glu | 624 (C → G) | BsmAI (c) |
2 | — | 730+ 35 (A → G) | PmlI (c) |
3 | Ala260Ala | 780 (A → G) | — |
3a | Thr353Ile | 1058 (C → T) | BsmAI (e) |
3c | — | 1515+ 73 (G → C) | — |
Table 4. Number of Study Subjects with Sequence Alterations Detected in the TIGR Gene
Table 4. Number of Study Subjects with Sequence Alterations Detected in the TIGR Gene
Sequence Alteration | Location | POAG Patients (%) (n = 91) | Family Members without Glaucoma (%) (n = 113) | Unrelated Control Subjects (%) (n = 132) |
1-83 (G → A) | Promoter | 11 (12) | 15 (13) | 23 (17) |
Gly12Arg (34G → C) | Exon 1 | 0 (0) | 3 (3) | 4 (3) |
Arg46Stop (136C → T) | Exon 1 | 1 (1) | 6 (5) | 4 (3), † |
Arg76Lys (227G → A) | Exon 1 | 11 (12) | 15 (13) | 23 (17) |
Arg91Stop (271C → T)* | Exon 1 | 1 (1) | 0 (0) | 0 (0) |
Asp208Glu (624C → G) | Exon 2 | 2 (2) | 1 (1) | 0 (0) |
730+ 35 (A → G) | Intron 2 | 35 (38) | 43 (38) | 41 (31) |
Ala260Ala (780A → G) | Exon 3 | 1 (1) | 0 (0) | — |
Thr353Ile (1058C → T) | Exon 3 | 3 (3) | 3 (3) | 3 (2) |
1515+ 73 (G → C) | 3′UTR | 1 (1) | 2 (2) | — |
Table 5. Genotype and Clinical Data of Patients with POAG with a Sequence
Alteration in the TIGR Gene
Table 5. Genotype and Clinical Data of Patients with POAG with a Sequence
Alteration in the TIGR Gene
Subject Number | Sex | Age at Diagnosis | Codon Change | Visual Acuity | | Highest Known IOP | | Vertical Cup-to-Disc Ratio |
| | | | OD | OS | OD | OS | |
P14 | F | 16 | Thr353Ile | 20/30 | 20/30 | 28 | 26 | 0.1/0.1 |
P161 | M | 4 | Arg46Stop | LP | 20/20 | 35 | 18 | 1.0/0.3 |
P179 | F | 49 | Asp208Glu | 20/30 | 20/30 | 24 | 26 | 0.3/0.3 |
P184 | M | 50 | Arg91Stop | 20/20 | 20/50 | 34 | 32 | 0.3/0.3 |
P187 | F | 69 | Thr353Ile | 20/20 | 20/70 | 37 | 25 | 0.5/0.5 |
P208 | F | 24 | Asp208Glu | 5/200 | 20/30 | 36 | 16 | 0.9/0.8 |
P211 | M | 67 | Thr353Ile | 18/200 | 18/200 | 26 | 28 | 0.3/0.4 |
Table 6. Genotype and Clinical Data of Subjects without POAG but with Arg46Stop
Mutation in the TIGR Gene
Table 6. Genotype and Clinical Data of Subjects without POAG but with Arg46Stop
Mutation in the TIGR Gene
Subject Number | Sex | Age at Examination | Visual Acuity | | Highest Known IOP | |
| | | OD | OS | OD | OS |
† >P159 | F | 39 | 20/30 | 20/30 | 17 | 17 |
P160 | M | 37 | 20/15 | 20/20 | 15 | 13 |
P229 | F | 12 | 20/30 | 20/30 | 16 | 16 |
P234 | M | 44 | 20/20 | 20/30 | 12 | 14 |
P235 | M | 43 | 20/15 | 20/15 | 12 | 12 |
P236 | F | 16 | 20/30 | 20/30 | 16 | 17 |
C155 | F | 66 | 20/40 | 20/40 | 30* | 16 |
C172 | M | 85 | 20/200 | HM | 16 | 15 |
C177, † | F | 77 | 20/70 | 20/50 | 11 | 11 |
C182 | F | 79 | 20/30 | 20/70 | 13 | 10 |
The authors thank Fion Lau for her contribution in contacting
subjects and collecting blood samples.
Thylefors B, Negrel A. The global impact of glaucoma. World Health Organ Bull Org Monidale Sante. 1994;72:323–326.
Wilson R, Martone J. Epidemiology of chronic open-angle glaucoma. Ritch R Shields M Krupin T eds. The Glaucomas. 1996;Vol 2:753–768. Mosby St Louis.
Stewart WC. The effect of lifestyle on the relative risk to develop open-angle glaucoma. Curr Opin Ophthalmol. 1995;6:3–9.
Wolfs RCW, Klaver CW, Ramrattan RS, van Duijn CM, Hofman A, de Jong PTVM. Genetic risk of primary open angle glaucoma. Arch Ophthalmol
. 1998;116:1640–1645.
[CrossRef] [PubMed]Raymond V. Molecular genetics of the glaucomas: mapping of the first five “GLC” loci. Am J Hum Genet
. 1997;60:272–277.
[PubMed]Booth A, Churchill A, Anwazr R, Menage M, Markham A. The genetics of primary open angle glaucoma. Br J Ophthalmol
. 1997;81:409–414.
[CrossRef] [PubMed]Wirtz MK, Samples JR, Rust K, et al. GLC1F, a new primary open-angle glaucoma locus, maps to 7q35–q36. Arch Ophthalmol
. 1999;117:237–241.
[CrossRef] [PubMed]Stone EM, Fingert JH, Alward LM, et al. Identification of a gene that causes primary open angle glaucoma. Science
. 1997;275:668–670.
[CrossRef] [PubMed]Kubota R, Noda S, Wang Y, et al. A novel myosin-like protein (myocilin) expressed in the connecting cilium of the photoreceptor: molecular cloning, tissue expression, and chromosomal mapping. Genomics
. 1997;41:360–369.
[CrossRef] [PubMed]Adam MF, Belmouden A, Binisti P, et al. Recurrent mutations in a single exon encoding the evolutionarily conserved olfactomedia-homology domain of TIGR in familial open-angle glaucoma. Hum Mol Gen
. 1997;6:2091–2097.
[CrossRef] [PubMed]Kubota R, Kudoh J, Mashima Y, et al. Genomic organization of the human myocilin gene (MYOC) responsible for primary open angle glaucoma. Biochem Biophys Res Commun
. 1998;242:396–400.
[CrossRef] [PubMed]Nguyen TD, Chen P, Huang WD, et al. Gene structure and properties of TIGR, an olfactomedin-related glycoprotein cloned from glucorticoid-induced trabecular meshwork cells. J Biol Chem
. 1998;273:6341–6350.
[CrossRef] [PubMed]Alward WLM, Fingert JH, Coote MA, et al. Clinical features associated with mutations in the chromosome 1 open-angle glaucoma gene (GLC1A). N Engl J Med
. 1998;338:1022–1027.
[CrossRef] [PubMed]Rozsa FW, Shimizu S, Lichter PR, et al. GLC1A mutations point to regions of potential functional importance on the TIGR/MYOC protein. Mol Vision. 1998;4:20.
Adam MF, Belmouden A, Binisti P, et al. Recurrent mutations in a single exon encoding the evolutionarily conserved olfactomedin-homology domain of TIGR in familial open-angle glaucoma. Hum Mol Gen
. 1997;6:2091–2097.
[CrossRef] [PubMed]Stoilova D, Child A, Brice G, Crick RP, Fleck BW, Sarfarazi M. Identification of a new ‘TIGR’ mutation in a family with juvenile-onset primary open angle glaucoma. Ophthalmic Genet
. 1997;18:109–118.
[CrossRef] [PubMed]Stoilova D, Child A, Brice G, et al. Novel TIGR/MYOC mutations in families with juvenile onset primary open angle glaucoma. J Med Genet
. 1998;35:989–992.
[CrossRef] [PubMed]Fingert JH, Héon E, Liebmann JM, et al. Analysis of myocilin mutations in 1703 glaucoma patients from five different populations. Hum Mol Gen
. 1999;8:899–905.
[CrossRef] [PubMed]Allingham RR, Wiggs JL, de la Paz MA, et al. Gln368STOP myocilin mutation in families with late-onset primary open-angle glaucoma. Invest Ophthalmol Vis Sci
. 1998;39:2288–2295.
[PubMed]Suzuki Y, Shirato S, Taniguchi F, Ohara K, Nishimaki K, Ohta S. Mutations in the TIGR gene in familial primary open-angle glaucoma in Japan. Am J Hum Genet
. 1997;61:1202–1204.
[CrossRef] [PubMed]Michels-Rautenstrauss KG, Mardin CY, Budde WM, et al. Juvenile open angle glaucoma: fine mapping of the TIGR gene to 1q24.3-q25.2 and mutation analysis. Hum Genet
. 1998;102:103–106.
[CrossRef] [PubMed]Morissette J, Côté G, Anctil JL, et al. A common gene for juvenile and adult-onset primary open-angle glaucomas confined on chromosome 1q. Am J Hum Genet
. 1995;56:1431–1442.
[PubMed]Morissette J, Clépet C, Moisan S, et al. Homozygotes carrying an autosomal dominant
TIGR mutation do not manifest glaucoma. Nat Genet
. 1998;19:319–321.
[CrossRef] [PubMed]Mansergh FC, Kenna PF, Ayuso C, Kiang AS, Humphries P, Farrar GJ. Novel mutations in the TIGR gene in early and late onset open angle glaucoma. Hum Mutat
. 1998;11:244–251.
[CrossRef] [PubMed]Richards JE, Ritch R, Lichter PR, et al. Novel trabecular meshwork inducible glucocorticoid response mutation in an eight-generation juvenile-onset primary open-angle glaucoma pedigree. Ophthalmology
. 1998;105:1698–1707.
[CrossRef] [PubMed]Yoon SJK, Kim HS, Moon JI, Lim JM, Joo CK. Mutations of the
TIGR/MYOC gene in primary open-angle glaucoma in Korea. Am J Hum Genet
. 1999;64:1775–1778.
[CrossRef] [PubMed]Anderson DR. Automated Static Perimetry. 1992;12. Mosby-Year Book St. Louis.
Ganguly A, Rock MJ, Prockop DJ. Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: Evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci USA
. 1993;90:10325–10329.
[CrossRef] [PubMed]Körkkö J, Annunen S, Pihlajamaa T, Prockop DJ, Ala-Kokko L. Conformation sensitive gel electrophoresis for simple and accurate detection of mutations: comparison with denaturing gradient gel electrophoresis and nucleotide sequencing. Proc Natl Acad Sci USA
. 1998;95:1681–1685.
[CrossRef] [PubMed]Kawase K, Alward WLM, Kawase C, et al. Sequence variation of GLC1A (MYOC/TIGR) gene in Japanese patients with normal-tension glaucoma and ocular hypertension [ARVO abstract]. Invest Ophthalmol Vis Sci. 1998;40(4)S78.Abstract nr 416
Underwood-Hu JL, Lin SC, Franse-Carman I, Alvarado JA. ZO-1 and TIGR expression in human trabecular meshwork cells [ARVO abstract]. Invest Ophthalmol Vis Sci. 1999;40(4)S669.Abstract nr 3533
Vollrath D, Zhou Z. A functional assay that distinguishes normal and glaucomatous mutant forms of TIGR/myocilin protein [ARVO abstract]. Invest Ophthalmol Vis Sci. 1999;40(4)S76.Abstract nr 405